Alyeska Investment Group
SCPH

Alyeska Investment Group’s scPharmaceuticals SCPH Stock Holding History

Alyeska Investment Group’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-355,690
Closed -$2.37M – 821
2021
Q1 		$2.37M Hold
355,690
– – 0.03% 444
2020
Q4 		$1.88M Sell
355,690
-2,845
-0.8% -$22.3K 0.03% 377
2020
Q3 		$2.67M Sell
358,535
-30,068
-8% -$235K 0.04% 319
2020
Q2 		$2.86M Buy
+388,603
New +$3.41M 0.04% 327
2019
Q1 		– Sell
-177,135
Closed -$666K – 444
2018
Q4 		$666K Sell
177,135
-53,684
-23% -$252K 0.01% 323
2018
Q3 		$1.35M Hold
230,819
– – 0.01% 329
2018
Q2 		$1.31M Buy
230,819
+7,381
+3% +$75.8K 0.01% 378
2018
Q1 		$2.77M Buy
223,438
+48,438
+28% +$651K 0.02% 328
2017
Q4 		$2.12M Buy
+175,000
New +$2.47M 0.02% 335

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Alyeska Investment Group's SCPH Position: Q2 2021 in Review

Alyeska Investment Group sold out of scPharmaceuticals (SCPH) in Q2 2021, closing a stake of 355,690 shares — an estimated $2.37M sold.

Alyeska Investment Group first reported a position in SCPH in Q4 2017 and held it in 9 quarters. The position peaked at $2.86M in Q2 2020. 38 funds tracked by Wall St. Rank hold SCPH as of Q2 2021.

  • Alyeska Investment Group reported no remaining scPharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 355,690 scPharmaceuticals shares in Q2 2021, an estimated $2.37M.
  • Alyeska Investment Group first reported a position in scPharmaceuticals in Q4 2017 and held it in 9 quarters.
  • Alyeska Investment Group's scPharmaceuticals position peaked at $2.86M in Q2 2020.
  • 38 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.